Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $23
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $25 to $23.
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $25 to $23.